Last reviewed · How we verify
NCT06984731
The Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion.
trial testing left atrial appendage closure in Cardiovascular Diseases in 210 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Affiliated Hospital of Nantong University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 210 |
| Start date | 21 April 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- left atrial appendage closure
- radiofrequency ablation
Conditions studied
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Arrhythmia — all drugs for Arrhythmia →
Sponsor
Affiliated Hospital of Nantong University
Who can join
Adults 18 to 80, any sex, with Cardiovascular Diseases or Arrhythmia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To evaluate the safety and efficacy of transcatheter atrial fibrillation ablation 1 month after WATCHMAN FLX left atrial appendage closure in patients with nonvalvular atrial fibrillation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06984731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of left atrial appendage closure
Trials testing the same drug.
- NCT06405750 — Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate · NA · recruiting
Other recruiting trials for Cardiovascular Diseases
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Affiliated Hospital of Nantong University trials
Trials by the same sponsor.
- NCT07506668 — RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas · Phase 1, PHASE2 · not yet recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07382453 — Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases · Phase 2 · not yet recruiting
- NCT07247838 — Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke · recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06984731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Nantong University
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06984731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing